For the visual health of the next generation
Short-sightedness (myopia) is currently one of the fastest-growing vision problems worldwide – especially among children and adolescents. Studies show that both genetic factors and changing visual habits contribute to the progression of myopia.
The application of the myopic defocus concept is currently among the most effective solutions.
- Central single-vision zone Ø 9 – 12 mm with prescription value.
- Degression selectable based on the wearer’s age for the defocus zone towards the lens edge.
Uncorrected
myopic eye
Corrected eye with
conventional lens
Corrected eye with
MyoSight lens
- 2.5 D total defocus
- For children aged 5 to 8
- 25% thinner than a single vision lens
- 1.6 D total defocus
- For adolescents aged 9 to 12
- 18% thinner than a single vision lens
- 1.0 D total defocus
- For adolescents aged 13 to 17
- 10% thinner than a single vision lens
MyoSight was developed to provide young eyes with effective, practical support in the fight against myopia progression. Our white paper details how the innovative freeform design with circular defocus works and why it is among the most effective non-invasive solutions in myopia management.
Particularly valuable: The white paper summarizes the results of a prospective, randomized, controlled double-blind study in which MyoSight’s effectiveness was scientifically proven. After just 12 months, the 6- to 9-year-old age group showed a significant slowing of myopia progression and a 32% lower increase in axial eye length compared to conventional single vision lenses. As described in the white paper: “The data to date support the use of MyoSight lenses as an effective, non-invasive measure to control the progression of myopia.”
The white paper offers a compact, well-founded overview of design, technology, clinical data, and practical application – ideal for opticians who want to offer myopia management at the highest level.
